Biallelic expression of IGF2 is frequently observed in cancers due to DNA methyltransferase 1 (DNMT1)-mediated de novo methylation of the ICR, a process called loss of imprinting (LOI) [11, 34]. This evidence concerns the gene DNMT1 and cancer.